Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.54B | 6.85B | 7.73B | 7.55B | 7.66B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.54B | 6.85B | 7.73B | 7.55B | 7.66B |
| Cost of Revenue | 2.51B | 2.84B | 2.60B | 2.58B | 2.66B |
| Gross Profit | 5.02B | 4.01B | 5.13B | 4.97B | 5.00B |
| SG&A Expenses | 1.77B | 1.83B | 1.83B | 1.72B | 1.77B |
| Depreciation & Amortization | 652.03M | 650.98M | 883.48M | 891.10M | 895.50M |
| Other Operating Expenses | 328.51M | -402.30M | 435.57M | 109.33M | 165.69M |
| Total Operating Expenses | 6.30B | 6.09B | 6.89B | 6.39B | 6.49B |
| Operating Income | 1.24B | 760.92M | 838.68M | 1.15B | 1.17B |
| Income Before Tax | 1.01B | -2.85B | 868.61M | 191.04M | 1.04B |
| Income Tax Expenses | 305.61M | -542.18M | 195.51M | 270.58M | 182.45M |
| Earnings from Continuing Operations | 699.79M | -2.31B | 673.10M | -79.54M | 860.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -370.70K | -388.10K | -609.90K | -488.20K | -249.30K |
| Net Income | 699.42M | -2.31B | 672.49M | -80.03M | 860.22M |
| EBIT | 1.24B | 760.92M | 838.68M | 1.15B | 1.17B |
| EBITDA | 2.25B | 1.21B | 2.08B | 2.41B | 2.43B |
| EPS Basic | 0.44 | -1.46 | 0.43 | -0.05 | 0.55 |
| Normalized Basic EPS | 0.40 | 0.18 | 0.29 | 0.35 | 0.37 |
| EPS Diluted | 0.44 | -1.46 | 0.42 | -0.05 | 0.54 |
| Normalized Diluted EPS | 0.39 | 0.18 | 0.29 | 0.35 | 0.37 |
| Average Basic Shares Outstanding | 1.58B | 1.58B | 1.58B | 1.58B | 1.56B |
| Average Diluted Shares Outstanding | 1.60B | 1.58B | 1.61B | 1.58B | 1.59B |
| Dividend Per Share | -- | 0.63 | 0.00 | 0.68 | -- |
| Payout Ratio | 132.63% | -2.38% | 143.80% | -74.45% | 116.94% |